Description PI3 Kinase is an oncogene that is commonly mutated in cancer. The PI3K/Akt/mTOR pathway regulates cell growth and survival.

Development Status Phase I dose escalation trials evaluating GDC-0941 for solid tumors or non-Hodgkin's lymphoma are ongoing. Phase Ib clinical trials for metastatic breast cancer and metastatic non-small cell lung cancer are ongoing evaluating GDC-0941 in combination with targeted medicines, such as Avastin® (bevacizumab), Herceptin® (trastuzumab), and Tarceva® (erlotinib); and in combination with an investigational targeted agent, trastuzumab emtansine (T-DM1). A Phase II clinical trial evaluating both GDC-0941 and GDC-0980 for second-line Estrogen Receptor-positive metastatic breast cancer is planned.

This molecule was discovered by Piramed Ltd. which was acquired by F. Hoffmann-La Roche.

For Avastin full prescribing information, including Boxed WARNINGS and additional important safety information, please visit http://www.avastin.com.

For Herceptin full prescribing information, including Boxed WARNINGS and additional important safety information, please visit http://www.herceptin.com.

For Tarceva full prescribing information, including additional important safety information, please visit http://www.tarceva.com or call 1-877-TARCEVA.

Additional Information on Clinical Trials For inquiries about our clinical trials, please submit a request through our information request form or call (888) 662-6728.

National Institutes of Health Website: www.clinicaltrials.gov

April 2011